Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is a Healthcare company (Biotechnology) with a market capitalization of $168M. The Maz Rating grades it against the other companies in its sector.
Oramed Pharmaceuticals Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.87, Oramed Pharmaceuticals Inc. trades at 1.1x trailing earnings and 0.5x book value, with an EV/EBITDA of 1.2. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of 52.9%, return on invested capital of -3.2% and a free cash flow yield of -1.7%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 6.07. Over the past 52 weeks the share price ranged from $2.32 to $5.47, with a beta of 1.28.
Oramed Pharmaceuticals Inc. pays a dividend yielding 6.41%, with 7% of earnings paid out. Its Maz Dividend Score is 4.77 out of 5, ranked against the other dividend payers in its sector (Safety 4.77, Growth 1.37, Yield 4.43).
8 Wall Street analyst ratings cover the stock: 6 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.